Peptides: Important tools for the treatment of central nervous system disorders

Neuropeptides

Volumn 45, Issue 5, 2011, Pages 309-316

  Malavolta, Luciana ^a   Cabral, Francisco Romero ^a  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

Blood brain barrier; CNS diseases; Drug delivery; Nanoparticles; Nanotechnology; Peptides

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA INTERFERON; BETA INTERFERON; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CALCITONIN; DORNASE ALFA; ENKEPHALIN; EPIDERMAL GROWTH FACTOR; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GLUCOSYLCERAMIDASE; GONADORELIN; GROWTH HORMONE; HIRUDIN; IMIGLUCERASE; INSULIN; OXYTOCIN; PEPTIDE; PROINSULIN; RECOMBINANT INTERLEUKIN 2; SOMATOMEDIN; SOMATOSTATIN; STREPTOKINASE; SUPEROXIDE DISMUTASE; TRIPROAMYLIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ANTIDIURESIS; BLOOD BRAIN BARRIER; BONE DISEASE; BRAIN; BRAIN DISEASE; CARCINOMA; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CYSTIC FIBROSIS; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG STABILITY; DRUG UPTAKE; ERYTHROPOIESIS; FIBRINOLYSIS; GAUCHER DISEASE; HAIRY CELL LEUKEMIA; HEMOPHILIA; HEMOPHILIA B; HUMAN; LABOR INDUCTION; MICELLE; MOLECULAR WEIGHT; MULTIPLE SCLEROSIS; NANOTECHNOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; REVIEW; SHORT STATURE; VIRUS INFECTION; WOUND HEALING;

ANIMALS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; DRUG CARRIERS; FEMALE; HUMANS; MALE; NANOPARTICLES; PEPTIDES; QUALITY OF LIFE; RATS;

EID: 80052506389     PISSN: 01434179     EISSN: 15322785     Source Type: Journal    
DOI: 10.1016/j.npep.2011.03.001     Document Type: Review

References (126)

1. Abusriwil H., Stockley R.A. Alpha-1-antitrypsin replacement therapy: current status. Curr. Opin. Pulm. Med. 2006, 12:125-131.
2. Acartürk F., Degi{dotless}m Z., Degi{dotless}m T. Investigation of the absorption of insulin through vagina in rabbits, AAPS Annual Meeting and Exposition. 10-14 November 2002, Toronto, Canada.
3. Ahn J.M., Boyle N.A., MacDonald M.T., Janda K.D. Peptidomimetics and peptide backbone modifications. Mini Rev. Med. Chem. 2002, 2:463-473.
4. Ajay B.G.W., Murcko M.A. Designing libraries with CNS activity. J. Med. Chem. 1999, 42:4942-4951.
5. Aktas Y., Yemisci M., Andrieux K., Gürsoy R.N., Alonso M.J., Fernandez-Megia E., Novoa-Carballal R., Quiñoá E., Riguera R., Sargon M.F., Celik H.H., Demir A.S., Hincal A.A., Dalkara T., Capan Y.C. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug. Chem. 2005, 16:1503-1511.
6. Albrecht M.A., Evans C.W., Raston C.L. Green chemistry and the health implications of nanoparticles. Green Chem. 2006, 8:417-432.
7. Alescio-Lautier B., Paban V., Soumireu-Mourat B. Neuromodulation of memory in the hippocampus by vasopressin. Eur. J. Pharmacol. 2000, 405:63-72.
8. Alyautdin R.N., Tezikov E.B., Ramge P., Khakevich D.A., Begley D.J., Kreuter J. Significant entry of tubocurarine into the brain of rats by absorption to polysorbate 80-coated polybutyl-cyanoacrylate nanoparticles: an in situ brain perfusion study. J. Microencapsul. 1998, 15:67-74.
9. Ang V.T., Jenkins J.S. Blood-cerebrospinal fluid barrier to arginine-vasopressin, desmopressin and desglycinamide arginine-vasopressin in the dog. J. Endocrinol. 1982, 93:319-325.
10. Audie J., Boyd C. The synergistic use of computation, chemistry and biology to discover novel peptide-based drugs: the time is right. Curr. Pharm. Design 2010, 16:567-582.
11. Bakshi P., Wolfe M.S. Stereochemical analysis of (hydroxyethyl) urea peptidomimetic inhibitors of gamma-secretase. J. Med. Chem. 2004, 47:6485-6489.
12. Banga A.K. Structure and Analysis of Therapeutic Peptides and Proteins. In Therapeutic Peptides and Proteins: Formulation, Processing and Delivery Systems 1995, Technomic Publishing Co. Inc., Pennsylvania.
13. Banks W.A., Kastin A.J. A brain-to-blood carrier-mediated transport system for small, N-tyrosinated peptides. Pharmacol. Biochem. Behav. 1984, 21:943-946.
14. Banks W.A., Schally A.V., Barrera C.M., Fasold M.B., Durham D.A., Csernus V.J., Groot K., Kastin A.J. Permeability of the murine blood-brain barrier tosome octapeptide analogs of somatostatin. Proc. Natl. Acad. Sci. USA 1990, 87:6762-6766.
15. Banks W.A., Audus K.L., Davis T.P. Permeability of the blood-brain barrier to peptides: an approach to the development of therapeutically useful analogs. Peptides 1992, 13:1289-1294.
16. Barnabas W., Kumar S.M., Kumaraswamy S., Kokilampal P.S.K., Nallupillai P. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res. 2008, 1200:159-168.
17. Barrera C.M., Banks W.A., Fasold M.B., Kastin A.J. Effects of various reproductive hormones on the penetration of LHRH across the blood-brain barrier. Pharmacol. Biochem. Behav. 1992, 41:255-257.
18. Baskin D.G., Figlewicz D.P., Woods S.C., Porte D., Dorsa D.M. Insulin in the brain. Annu. Rev. Physiol. 1987, 49:335-347.
19. Batrakova E.V., Zhang Y., Li Y., Li S., Vinogradov S.V., Persidsky Y., Alakhov V.Y., Miller D.W., Kabanov A.V. Effects of Pluronic P85 on GLUT1and MCT1 transporters in the blood-brain barrier. Pharm. Res. 2004, 21:1993-2000.
20. Bickel U., Kang Y.S., Pardridge W.M. In vivo cleavability of a disulfide-based chimeric opioid peptide in rat brain. Bioconjug. Chem. 1995, 6:211-218.
21. Borm P.J., Kreyling W. Toxicological hazards of inhaled nanoparticles-potential implications for drug delivery. J. Nanosci. Nanotechnol. 2004, 4:521-531.
22. Brasnjevic I., Steinbusch H.W.M., Schmitz C., Martinez P.M. Delivery of peptide and protein drugs over the blood-brain barrier. Progress in Neurobiol. 2009, 87:212-251.
23. Brouwer A.J., Liskamp R.M.J. Synthesis of cyclic peptidosulfonamides by ring-closing metathesis. J. Org. Chem. 2004, 69:3662-3668.
24. Bryant W.P., O'Marcaigh A.S., Ledger G.A., Zimmerman D. Aqueous vasopressin infusion during chemotherapy in patients with diabetes insipidus. Cancer 1994, 74:2589-2592.
25. Caberlotto L., Fuxe K., Overstreet D.H., Gerrard P., Hurd Y.L. Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment. Mol. Brain Res. 1998, 59:58-65.
26. Capsoni S., Giannotta S., Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc. Natl. Acad. Sci. USA 2002, 99:12432-12437.
27. Colburn W.A., Gottlieb A.B., Koda J., Kolterman O.G. Pharmacokinetics and pharmacodynamics of AC137 (25, 28, 29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes. J. Clin. Pharmacol. 1996, 36:13-24.
28. Constantino L., Gandolfi F., Tosi G., Rivasi F., Vandelli M.A., Forni F. Peptide-derivatized biodegradable nanoparticles able to cross the blood brain barrier. J. Control. Rel. 2005, 108:84-96.
29. Das D., Lin S. Double-coated poly (butylcyanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. J. Pharm. Sci. 2005, 94:1343-1353.
30. Davis J.M., Rosenfeld W.N., Richter S.E., Parad R., Gewolb I.H., Spitzer A.R., Carlo W.A., Couser R.J., Price A., Flaster E., Kassem N., Edwards L., Tierney J., Horowitz S. Safety and pharmacokinetics of multiple doses of recombinant human CuZn superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome. Pediatrics 1997, 100:24-30.
31. Degim T., Celebi N. Controlled delivery of peptides and proteins. Curr. Pharm. Design 2007, 13:99-117.
32. Delgado M., Ganea D. Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J. 2003, 17:1922-1924.
33. Dogrukol-Ak D., Tore F., Tuncel N. Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects. Curr. Pharm. Des. 2004, 10:1325-1340.
34. Durham D.A., Banks W.A., Kastin A.J. Carrier-mediated transport of labeled oxytocin from brain to blood. Neuroendocrinology 1991, 53:447-452.
35. Egleton R.D., Davis T.P. Bioavailability and transport of peptides and peptide drugs into the brain. Peptides 1997, 18:1431-1439.
36. Eschbach J.W., Egrie J.C., Downing M.R., Browne J.K., Adamson J.W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N. Engl. J. Med. 1987, 316:73-78.
37. Fagerholm U. The highly permeable blood-brain barrier: an evaluation of current opinions about brain uptake capacity. Drug Discov. Today 2007, 12:1076-1082.
38. Figlin R.A., Belldegrun A., Moldawer N., Zeffren J., Dekernion J. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2a - an active outpatient regimen in metastatic renal-cell carcinoma. J. Clinical Oncol. 1992, 10:414-421.
39. Fletcher M.D., Campbell M.M. Partially modified retro-inverso peptides: development, synthesis, and conformational behavior. Chem. Rev. 1998, 98:763-795.
40. Folkers P.J.M., Clore G.M., Driscoll P.C., Dodt J., Kohler S., Gronenborn A.M. Solution structure of recombinant hirudin and the lys-47-] glu mutant - a nuclear magnetic-resonance and hybrid distance geometry dynamical simulated annealing study. Biochem. 1989, 28:2601-2617.
41. Gao X., Wu B., Zhang Q., Chen J., Zhu J., Zhang W., Rong Z., Chen H., Jiang X. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J. Control. Rel. 2007, 121:156-167.
42. Gentilucci L. New trends in the development of opioid peptide analogues as advanced remedies for pain relief. Curr. Top. Med. Chem. 2004, 4:19-38.
43. Gentilucci L., Tolomelli A., Squassabia F. Peptides and peptidomimetics in medicine, surgery and biotechnology. Curr. Med. Chem. 2006, 13:2449-2466.
44. Goody A.R. The production of heterologous plasma proteins. Trends Biotechnol. 1993, 11:430-433.
45. Grabowski G.A., Barton N.W., Pastores G., Dambrosia J.M., Banerjee T.K., Mckee M.A., Parker C., Schiffmann R., Hill S.C., Brady R.O. Enzyme therapy in type 1 gaucher disease comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med. 1995, 122:33-39.
46. Greene D.L., Hau V.S., Abbruscato T.J., Bartosz H., Misicka A., Lipkowski A.W., Hom S., Gillespie T.J., Hruby V.J., Davis T.P. Enkephalin analog prodrug: assessment of an in vitro conversion, enzyme cleavage characterization and blood-brain barrier permeability. J. Pharm. Exp. Ther. 1996, 277:1366-1375.
47. Grislain L., Couvreur P., Lenaerts V., Roland M., Deprez-Decampeneere D., Speiser P. Pharmacokinetics and distribution of a biodegradable drug-carrier. Int. J. Pharm. 1983, 15:335-345.
48. Gulyaev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Y. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 1999, 16:1564-1569.
49. Gurny R., Peppas N.A., Harrington D.D., Banker G.S. Development of biodegradable and injectable lattices for controlled release of potent drugs. Drug Dev. Ind. Pharm. 1981, 7:1-25.
50. Gutierrez E.G., Banks W.A., Kastin A.J. Murine tumor necrosis factor alpha is transported from blood to brain in the mouse. J. Neuroimmunol. 1993, 47:169-176.
51. Horowitz M., Zimran A. Mutations causing gaucher disease. Hum. Mutat. 1994, 3:1-11.
52. Horwell D.C. The peptoid approach to the design of nonpeptide, small-molecule agonists and antagonists of neuropeptides. Trends Biotechnol. 1995, 13:132-134.
53. Janecka A., Perlikowska R., Gach K., Wyrebska A., Fichna J. Development of opioid peptide analogs for pain relief. Curr. Pharm. Design 2010, 16:1126-1135.
54. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Del. Rev. 2001, 47:65-81.
55. Krieger D.T. Brain peptides: what, where, and why?. Science 1983, 222:975-985.
56. Kulkarni P.V., Roney C.A., Antich P.P., Bonte F.J., Raghu A.V., Aminabhavi T.M. Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2010, 2:35-47.
57. Kumar S.T.R., Soppimath K., Nachaegari S.K. Novel delivery technologies for protein and peptide therapeutics. Curr. Pharm. Biotechnol. 2006, 7:261-276.
58. Landry F.B., Bazile D.V., Spenlehauer G., Veillard M., Kreuter J. Influence of coating agents on the degradation of poly (lactic acid) nanoparticles in model digestive fluids. Pharm. Sci. 1996, 63:195-202.
59. Lee J.H., Engler J.A., Collawn J.F., Moore B.A. Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur. J. Biochem. 2001, 268:2004-2012.
60. Levinson B., Kenwrick S., Lakich D., Hammonds G., Gitschier J. A transcribed gene in an intron of the human factor VIII gene. Genomics 1990, 7:1-11.
61. Li C., Newman R.A., Wu Q.P., Ke S., Chen W., Hutto T., Kan Z., Brannan M.D., Charnsangavej C., Wallace S. Biodistribution of paclitaxel and poly (L-glutamic acid)-paclitaxel conjugate in mice with OCa-1 tumor. Cancer Chemother. Pharmacol. 2000, 46:416-422.
62. Liu G., Men P., Kudo W., Perry G., Smith M.A. Nanoparticle-chelator conjugates as inhibitors of amyloid-β aggregation and neurotoxicity: A novel therapeutic approach for Alzheimer disease. Neurosci. Lett. 2009, 455:187-190.
63. Lucke A., Fustella E., Tessmar J., Gazzaniga A., Gopferich A. The effect of poly(ethylene glycol)-poly(D, L-lactic acid) diblock copolymers on peptide acylation. J. Control. Rel. 2002, 80:157-168.
64. Mackay M., Phillips J., Hastewell J. Peptide drug delivery: colonic and rectal absorption. Adv. Drug Del. Rev. 1997, 28:253-273.
65. Malakoutikhah M., Prades R., Teixido M., Giralt E. N-Methyl phenylalanine-rich peptides as highly versatile blood brain barrier shuttles. J. Med. Chem. 2010, 53:2354-2363.
66. Malavolta L., Cabral F.R., Conterras L.F.G., Ringheim A.M., Bressan R.A. Use of peptides combine with nanotechnology and molecular imaging-new tools for diagnosis and treatment of neuropsychiatric disorders. Rev. Bras. Psiquiatr. 2009, 31:300-302.
67. Marty J.J., Oppenheim R.C., Speiser P. Nanoparticles - a new colloidal drug delivery system. Pharm. Acta Helv. 1978, 53:17-23.
68. Milas L., Mason K.A., Hunter N., Li C., Wallace S. Poly(L-glutamic acid)-paclitaxel conjugated is a potent enhancer of tumor radiocurability. Int. J. Radiat. Oncol. Biol. Phys. 2003, 55:707-712.
69. Modi G., Pillay V., Choonara Y.E., Ndesendo V.M.K., du Toit L.C., Naidoo D. Nanotechnological applications for the treatment of neurodegenerative disorders. Progress Neurobiol. 2009, 88:272-285.
70. Moghbeli N., Srinivas S.K., Bastek J., Lu Y., Putt M.E., Cappola T.P., Elovitz M.A. N-terminal pro-brain natriuretic peptide as a biomarker for hypertensive disorders of pregnancy. Am. J. Perinatol. 2010, 27:313-319.
71. Mosberg H.I., Hurst R., Hruby V.J., Gee K., Yamamura H.I., Galligan J.J., Burks T.F. Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors. Proc. Natl. Acad. Sci. 1983, 80:5871-5874.
72. Mundada L.V., Prorok M., DeFord M.E., Figuera M., Castellino F.J., Fay W.P. Structure-function analysis of the streptokinase amino terminus (residues 1-59). J. Biol. Chem. 2003, 278:24421-24427.
73. Mykhaylyk O., Cherchenko A., Ilkin A., Dudchenko N., Ruditsa V., Novoseletz M., Zozulya Y. Glial brain tumor targeting of magnetite nanoparticles in rats. J. Magn. Mater. 2001, 225:241-247.
74. Olsen S.K., Garbi M., Zampieri N., Eliseenkova A.V., Ornitz D.M., Goldfarb M., Mohammadi M. Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. J. Biol. Chem. 2003, 278:34226-34236.
75. Pan W., Kastin A.J. Entry of EGF into brain is rapid and saturable. Peptides 1999, 20:1091-1098.
76. Pan W., Kastin A.J. Interactions of IGF-1 with the blood-brain barrier in vivo and in situ. Neuroendocrinol. 2000, 72:171-178.
77. Pardridge W.M. Peptide Drug Delivery to the Brain 1991, Raven Press, New York, NY.
78. Pardridge W.M. Brain Drug Targeting: The Future of Brain Drug Development 2001, Cambridge University Press, Cambridge, UK.
79. Pardridge W.M. Editorial: the blood-brain barrier and neurotherapeutics. J. Am. Soc. Exp. Neuro-Ther. 2005, 2:1.
80. Pasha S., Gupta K. Various drug delivery approaches to the central nervous system. Exp. Opinion Drug Deliv. 2010, 7:113-135.
81. Pontiroli A.E. Intranasal administration of calcitonin and of other peptides: studies with different promoters. J. Control. Rel. 1990, 13:247-251.
82. Ponzoni M., Casalaro A., Lanciotti M., Montaldo P.G., Cornagliaferraris P. The combination of gamma-interferon and tumor-necrosis-factor causes a rapid and extensive differentiation of human neuroblastoma-cells. Cancer Res. 1992, 52:931-939.
83. Pradhan A.D., Manson J.E., Meigs J.B., Rifai N., Buring J.E., Liu S., Ridker P.M. Insulin, proinsulin, proinsulin:insulin ratio, and the risk of developing type 2 diabetes mellitus in women. Am. J. Med. 2003, 114:438-444.
84. Pujals S., Sabido E., Tarrago T., Giralt E. All D-proline-rich cell penetrating peptides: a preliminary in vivo internalization study. Biochem. Soc. Trans. 2007, 35:794-796.
85. Qian Z.M., Li H., Sun H., Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 2002, 4:561-587.
86. Reglodi D., Lubics A., Tamas A., Szalontay L., Lengvari I. Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease. Behav. Brain Res. 2004, 151:303-312.
87. Rupniak N.M. Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists. Curr. Opin. Invest. Drugs 2002, 3:257-261.
88. Sagan S., Karoyan P., Lequin O., Chassaing G., Lavielle S. N- and C alpha-methylation in biologically active peptides: Synthesis, structural and functional aspects. Curr. Med. Chem. 2004, 11:2799-2822.
89. Santra S., Yang H., Dutta D., Stanley J.T., Holloway P.H., Tan W., Moudgil B.M., Mericle R.A. TAT conjugated, FITC doped silica nanoparticles for bioimaging applications. Chem. Commun. 2004, 24:2810-2811.
90. Sasubilli R., Gutheil W.G. General inverse solid-phase synthesis method for C-terminally modified peptide mimetics. J. Comb. Chem. 2004, 6:911-915.
91. Schroeder U., Sommerfeld P., Ulrich S., Sabel B.A. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J. Pharm. Sci. 1998, 87:1305-1307.
92. Segal M.B., Zlokovic B.V. Blood-Brain Barrier: Amino Acids and Peptides 1990, Kluwer Academic publishers, Lancaster and Boston, pp. 47-123.
93. Sharifi R., Knoll L.D., Smith J., Kramolowsky E. Leuprolide acetate (30 mg depot every four months) in the treatment of advanced prostate cancer. Urology 1998, 51:271-276.
94. Siegemund T., Paulke B.R., Schmiedel H., Bordag N., Hoffmann A. Thioflavins released from nanoparticles target fibrillar amyloid beta in the hippocampus of APP/PS1 transgenic mice. Int J. Dev. Neurosci. 2006, 24:195-201.
95. Sinha V.R., Bansal K., Kaushik R., Kumria R., Trehan A. Polycaprolactone microspheres and nanospheres: an overview. Int. J. Pharm. 2004, 278:1-23.
96. Sipos E., Kurunczi A., Fehér A., Penke Z., Fülöp L., Kasza A., Horváth J., Horvát S., Veszelka S., Balogh G., Kürti L., Eros I., Szabó-Révész P., Párducz A., Penke B., Deli M.A. Intranasal delivery of human β-amyloid peptide in rats: effective brain targeting. Cell Mol. Neurobiol. 2010, 30:405-413.
97. Smith P.L. Peptide delivery via the pulmonary route: a valid approach for local and systemic delivery. J. Control. Rel. 1997, 46:99-106.
98. Soares A.F., Carvalho R.A., Veiga F. Oral administration of peptides and proteins: nanoparticles and cyclodextrins as biocompatible delivery systems. Nanomed. 2007, 2:183-202.
99. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Rel. 2001, 70:1-20.
100. Spampinato S., Qasem A.R., Calienni M., Murari G., Gentilucci L., Tolomelli A., Cardillo G. Antinociception by a peripherally administered novel endomorphin-1 analogue containing beta-proline. Eur. J. Pharm. 2003, 469:89-95.
101. Stolnik S., Shakesheff K. Formulations for delivery of therapeutic proteins. Biotechnol. Lett. 2009, 31:1-11.
102. Tamai I., Sai Y., Koayashi H., Kamata M., Wakamiya T., Tsuji A. Structure- internalization relationship for adsorptive-mediated endocytosis of basic peptides at the blood-brain barrier. J. Pharm. Exp. Ther. 1997, 280:410-415.
103. Taran L.D. Factor IX of the blood coagulation system: a review. Biochem. Mosc. 1997, 62:685-693.
104. Teixidó M., Giralt E. The role of peptides in blood-brain barrier nanotechnology. J. Pept. Sci. 2008, 14:163-173.
105. Tilbery C.P., Felipe E., Moreira M.A., Mendes M.F., Franca A.S. Interferon beta 1-a in multiple sclerosis: experience of one year in 62 patients. Arq. Neuro-Psiquiatr. 2000, 58:452-459.
106. Tobío M., Sánchez A., Vial A., Soriano I., Évora C., Vila-Jato J.L., Alonso M.J. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticle following oral administration. Coll. Surf. B: Biointerf. 2000, 18:315-323.
107. Torchilin V.P., Rammohan R., Weissig V., Levchenko T.S. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl. Acad. Sci. 2001, 98:8786-8791.
108. Tosi G., Costantino L., Rivasi F., Ruozi B., Leo E., Vergoni A.V., Tacchi R., Bertolini A., Vandelli M.A., Forni F. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with loperamide and rhodamine-123. J. Control Rel. 2007, 122:1-9.
109. Tugyi R., Mezo G., Fellinger E., Andreu D., Hudecz F. The effect of cyclization on the enzymatic degradation of herpes simplex virus glycoprotein D derived epitope peptide. J. Pept. Sci. 2005, 11:642-649.
110. Vergoni A.V., Tosi G., Tacchi R., Vandelli M.A., Bertolini A., Costantino L. Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomed-Nanotechnol. Biol. Med. 2009, 5:369-377.
111. Veuillez F., Kalia Y.N., Jacques Y., Deshusses J., Buri P. Factors and strategies for improving buccal absorption of peptides. Eur. J. Pharm. Biopharm. 2001, 51:93-109.
112. von Roedern E.G., Lohof E., Hessler G., Hoffmann H., Kessler H. Synthesis and conformational analysis of linear and cyclic peptides containing sugar amino acids. J. Am. Chem. Soc. 1996, 118:10156-10167.
113. Weber S.J., Abbruscato T.J., Brownson E.A., Lipkowski A.W., Polt P., Misicka A., Haaseth R.C., Bartosz H., Hruby V.J., Davis T.P. Assessment of an in vitro blood-brain barrier model using several [Met5] enkephalin opioid analogs. J. Pharm. Exp. Ther. 1993, 266:1649-1655.
114. Weber S.J., Greene D.L., Sharma S.D., Yamamura H.I., Kramer T.H., Burks T.F., Hruby V.J., Hersh L.B., Davis T.P. Distribution and analgesia of [3H][D-Pen2, D-Pen5]enkephalin and two halogenated analogs after intravenous administration. J. Pharm. Exp. Ther. 1991, 259:1109-1117.
115. Weisskopf M.G., Zalutsky R.A., Nicoll R.A. The opioid peptide dynorphin mediates heterosynaptic depression of hippocampal mossy.bre synapses and modulates long-term potentiation. Nature 1993, 362:423-427.
116. Widder K.J., Senyei A.E., Ranney D.F. Magnetically responsive microspheres and other carriers for the biological targeting of antitumor agents. Adv. Pharmacol. Chemother. 1979, 16:213-271.
117. Williams S.A., Abbruscato T.J., Hruby V.J., Davis T.P. Passage of a δ-opioid receptor selective enkephalin [D-penicillamine2, 5]enkephalin, across the blood-brain and blood-cerebrospinal fluid barriers. J. Neurochem. 1996, 66:1289-1299.
118. Wilson B., Samanta M.K., Santhi K., Kumar K.P.S., Paramakrishnan N. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 2008, 70:75-84.
119. Witt D.M., Anderson L. Dornase alfa: a new option in the management of cystic fibrosis. Pharmacotherapy 1996, 16:40-48.
120. Witt K.A., Gillespie T.J., Huber J.D., Egleton R.D., Davis T.P. Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides 2001, 22:2329-2343.
121. Wu H.B., Hu K.L., Jiang X.G. From nose to brain: understanding transport capacity and transport rate of drugs. Exp. Opinion Drug Deliv. 2008, 5:1159-1168.
122. Wua T.J., Huanga H.H., Lana C.W. Studies on the microspheres comprised of reconstituted collagen and hydroxyapatite. Biomaterials 2004, 25:651-658.
123. Xiang J.J., Tang J.Q., Zhu S.G., Nie X.M., Lu H.B., Shen S.R., Li X.L., Tang K., Zhou M., Li G.Y. IONP-PLL: a novel non-viral vector for efficient gene delivery. J. Gene Med. 2003, 5:803-817.
124. Xiang J.J., Zhu S.G., Li G.Y. Using iron oxide nanoparticles as gene carrier. Chin. J. Cancer 2001, 20:1-6.
125. Xie Y.L., Lu W., Jiang X.G. Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice. Behav. Brain Res. 2006, 173:76-84.
126. Zega A. Azapeptides as pharmacological agents. Curr. Med. Chem. 2005, 12:589-597.